| Literature DB >> 18692243 |
Claudia Kemper1, Dennis E Hourcade.
Abstract
Properdin was first described over 50 years ago by Louis Pillemer and his collaborators as a vital component of an antibody-independent complement activation pathway. In the 1970s properdin was shown to be a stabilizing component of the alternative pathway convertases, the central enzymes of the complement cascade. Recently we have reported that properdin can also bind to target cells and microbes, provide a platform for convertase assembly and function, and promote target phagocytosis. Evidence is emerging that suggests that properdin interacts with a network of target ligands, phagocyte receptors, and serum regulators. Here we review the new findings and their possible implications.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18692243 PMCID: PMC2628304 DOI: 10.1016/j.molimm.2008.06.034
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407